Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

Leighl, NB; Karaseva, N; Nakagawa, K; Cho, BC; Gray, JE; Hovey, T; Walding, A; Ryden, A; Novello, S

Novello, S (corresponding author), Univ Turin, Dept Oncol, Azienda Osped Univ San Luigi Gonzaga, Reg Gonzole 10, I-10043 Turin, Italy.

EUROPEAN JOURNAL OF CANCER, 2020; 125 (): 49

Abstract

Background: In the FLAURA trial, osimertinib demonstrated superior progression-free survival and a favorable toxicity profile to erlotinib or gefitini......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索